Myeloma: A malignant disorder of bone and soft tissue
TLDR
Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that the authors do not have sufficient ability or knowledge to control this very troublesome disorder.Abstract:
The purpose of this brief report is to review a large series of cases of myeloma, a highly malignant tumor. The disease was first described over 150 years ago, but not named myeloma until 1873. The lesion appears to be caused by the production of plasma cells in the bone marrow occasionally associated with amyloid. Patients present with pain in bones, principally spine, pelvis, ribs, calvarium and long bones. The sedimentation rate is elevated and marrow shows 10% plasma cells and the sedimentation rate is always elevated. There is no identified genetic cause and the disease is not familial. The disease has a highly malignant potential. We treated 181 mature adult patients with tumor in multiple sites. 63% were dead of disease at an average of 4.5 years after diagnosis. The use of some new drugs have been helpful, chiefly lalanlidomide or bortezomib. Radiation appears to be useful for some lesions and bisphosphonates sometimes help support the bone structure. Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that we do not have sufficient ability or knowledge to control this very troublesome disorder.read more
References
More filters
Journal ArticleDOI
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
TL;DR: The possibility that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through paracrine and perhaps autocrine mechanisms is raised.
Journal ArticleDOI
Thalidomide in the management of multiple myeloma.
Bart Barlogie,Maurizio Zangari,Trey Spencer,Athanasios Fassas,Elias Anaissie,Ashraf Badros,Jeana Cromer,Guido Tricot +7 more
TL;DR: The virtual absence of myelosuppressive toxicity, except in heavily pretreated patients with compromised bone marrow function, suggests that thalidomide is an ideal agent to be used in combination with cytotoxic agents and dexamethasone.
Book ChapterDOI
Commentary on and reprint of Waldenström J, Incipient myelomatosis or “essential hyperglobulinemia with fibrinogenopenia”—a new syndrome?, in Acta Medica Scandinavica (1944) 117:216–247
Journal ArticleDOI
Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families.
Helga M. Ögmundsdóttir,Vilhelmína Haraldsdóttirm,Gudmundur Johannesson,Gudridur H Olafsdottir,Kristín Bjarnadóttir,Helgi Sigvaldason,Hrafn Tulinius +6 more
TL;DR: Although inheritance does not appear to be a major risk factor for the development of paraproteinemias a significant risk of developing MM was found for female relatives, and the occurrence of multiple cases of benign and malignant paraproteininemias in a few families does suggest a hereditary contribution.